ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Conference Call May 10, 2024 8:30 AM ET Company Participants Lisa Wilson - In-Site Communications, Investor Relations Nikhil Lalwani - President and Chief Executive Officer Stephen Carey - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Gary Nachman - Raymond James Leszek Sulewski - Truist Securities Vamil Divan - Guggenheim Securities Oren Livnat - H.C. Wainwright Timothy Chiang - Capital One Operator Good day, ...

ANI Pharmaceuticals (ANIP) reported $137.43 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 28.7%. EPS of $1.21 for the same period compares to $1.17 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $125.01 million, representing a surprise of +9.94%. The company delivered an EPS surprise of +23.47%, with the consensus EPS estimate being $0.98.While investors closely watch year-over-year changes in headline numbers -- revenue and earni ...

Table of Contents Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-31812 ANI ...

Generated record quarterly net revenues of $137.4 million, representing year-over-year growth of 28.7%, net income to common shareholders of $17.8 million, and GAAP diluted earnings per share of $0.82Delivered record adjusted non-GAAP EBITDA of $37.6 million, and adjusted non-GAAP diluted earnings per share of $1.21Rare Disease business delivered Q1 net revenues of $36.9 million, representing year-over-year growth of 126.2%Reiterated 2024 guidance of net revenues of $520 million to $542 million, adjusted no ...

Investors are always looking for stocks that are poised to beat at earnings season and ANI Pharmaceuticals, Inc. (ANIP) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because ANI Pharmaceuticals is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — ...

ANI Pharmaceuticals (ANIP) is slated to report first-quarter 2024 results on May 10, before the opening bell. Investors are advised to focus on the sales performance of the company’s core business segments — rare disease and generic business.The Zacks Consensus Estimate for the company’s earnings per share is currently pegged at 98 cents. The Zacks Consensus Estimate for total revenues is pinned at $125 million.Let's see how things might have shaped up for the upcoming quarterly release.Factors to ConsiderA ...

BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: Date Friday, May 10, 2024 Time 8:30 a.m. ET Toll free ( ...

BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateFriday, May 10, 2024  Time8:30 a.m. ET  Toll free ( ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering ANI Pharmaceuticals (ANIP) , which belongs to the Zacks Medical - Biomedical and Genetics industry.This drugmaker has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 46.05%.For the most recent quarter, ANI was expected to post earnings ...

BAUDETTE, Minn., April 09, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug (RLD) Fleqsuvy®. "The launch of Baclofen Oral Suspension represents another entry for ANI into a rapidly growing limited competition market. We are proud of our ability to recognize the market need and provide our customers with the best suited packing configurations to match their requirements ...